CelLBxHealth (CLBX) Q3 2026 TU earnings summary

Executive summary

• Q3 new business rose threefold YoY to £0.3m; 9M cash operating loss fell 60% to £4.0m, while FY 2026 revenue guidance was revised to ~£1.8m due to timing effects from operational realignment.

• FY 2027 revenue is expected to reach £3.0m–£4.0m, supported by stronger commercial momentum, an expanding pipeline and operational improvements.

Financial highlights

• Q3 revenue booked was £0.2m; new business secured was £0.3m versus £0.1m in Q3 2025.

• 9M cash operating loss decreased 60% YoY to £4.0m from £9.7m; cash and cash equivalents were £1.4m at 30 September 2026.

• FY 2026 revenue is expected at ~£1.8m, up 29% YoY from £1.4m in FY 2025; a further £0.1m of business was secured in early October.

Outlook and guidance

• Q4 investment in growth, product and service optimisation, and new product development is expected to raise average monthly cash expenditure by £0.1m from Q3's £0.4m cash burn.

• Following receipt of the anticipated £0.8m R&D tax credit, cash runway is expected to extend through Q1 2027.

• FY 2027 revenue guidance is £3.0m–£4.0m, reflecting anticipated commercial momentum, pipeline expansion and benefits of 2026 operational improvements.